Free shipping on all orders over $ 500

Denosumab

Cat. No. M8984

All AbMole products are for research use only, cannot be used for human consumption.

Denosumab Structure
Synonym:

AMG 162,Anti-RANK ligand

Size Price Availability Quantity
100ug USD 200  USD200 In stock
5mg USD 700  USD700 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?
Quality Control & Documentation
  • Purity: Reduced CE-SDS>95%
  • COA
  • MSDS
Biological Activity

Denosumab is designed to target RANKL (RANK ligand), a protein that acts as the primary signal to promote bone removal/resorption. Denosumab prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone.

In vivo, treatment with 60 mg of Denosumab resulted in reduction in the bone resorption marker serum type 1 C-telopeptide (CTX) by approximately 85% by 3 days. Consistent with the physiological coupling of bone formation and resorption in skeletal remodeling, subsequent reductions in bone formation markers (i.e. osteocalcin and procollagen type 1 N-terminal peptide [PlNP]) were observed starting 1 month after the first dose of Denosumab.

Chemical Information
Molecular Weight 144700
Formula C6404H9912N1724O2004S50
CAS Number 615258-40-7
Form Liquid
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Nagesha Guthalu Kondegowda, et al. Cell Metab. Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway

[2] Malan J, et al. Oral Surg Oral Med Oral Pathol Oral Radiol. The relationship of denosumab pharmacology and osteonecrosis of the jaws.

[3] Susann Helas, et al. Am J Pathol. Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice

[4] Lorenz C Hofbauer, et al. Arthritis Rheum. Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL

Related NF-κB Products
DCZ5418 

DCZ5418 is an inhibitor of TRIP13.
Ro 106-9920 

Ro 106-9920 is a potent inhibitor of NF-kappaB.
MRS2693 trisodium 

MRS2693 trisodium is a selective P2Y6 agonist with an EC50 value of 0.015 μM.
PTD-p65-P1 Peptide TFA

PTD-p65-P1 Peptide TFA is a potent, selective nuclear transcription factor NF-κB inhibitor and derives from the p65 subunit of NF-κB amino acid residues 271-282, which selectively inhibits NF-κB activation induced by various inflammatory stimulation, down-regulate NF-κB-mediated gene expression and up-regulate apoptosis.
Narlumosbart

Narlumosbart is a human IgG4ҡ monoclonal antibody (mAb) that targets Receptor Activating Factor for Nuclear Factor κB Ligand (RANKL) and can be used in studies related to Giant Cell Tumor of Bone (GCTB).
  Catalog
Abmole Inhibitor Catalog




Keywords: Denosumab, AMG 162,Anti-RANK ligand supplier, NF-κB, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.


 
Get to Know Us
Customer Support
Resources
Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.